Search This Blog

Wednesday, September 11, 2019

FDA to review United Therapeutics application for Trevyent

The FDA has accepted for review United Therapeutics’ (NASDAQ:UTHR) NDA for Trevyent (treprostinil) for the treatment of pulmonary arterial hypertension (PAH).
PDUFA target action date is April 27, 2020.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)